Evaluating the Impact of MyTatva Application in Managing Type II Diabetes in Real-World Settings

A Real World evidence study to evaluate the Impact of MyTatva Application in the Management of Type II Diabetes Mellitus - NIL

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/071851

Enrollment

Registered

2024-08-02

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: MyTatva Mobile Application: The MyTatva App is a digital platform for patients with Type II Diabetes that provides lifestyle intervention for a duration of 3 months, through a personali

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female aged at least 18 years with confirmed diagnosis of Type II Diabetes Mellitus. 2. Subject diagnosed with Type II Diabetes Mellitus with HbA1c 7.5% to 9.5%. 3. Patients with access to a smartphone with internet access/data plan. 4. Patients who understand and speak English sufficiently to be able to use the MyTatva Patient application. 5. Patient is willing to comply with all study procedures and is available for the duration of the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
•The percentage of patients with improvement in Time in Range (TIR) from the baseline (first 2 weeks) to the end of 12 weeks (last 2 weeks) •The percentage of patients with reduction in Time above Range (TAR) from the baseline (first 2 weeks) to the end of 12 weeks (last 2 weeks) •The percentage of patients with improvement in Time below Range (TBR) from the baseline (first 2 weeks) to the end of 12 weeks (last 2 weeks) •The percentage of patients with improvement in FBG (mg/dL) from baseline to the end of 12 weeks. •The percentage of patients with improvement in PPBG (mg/dL) from baseline to the end of 12 weeks. •The percentage of patients with reduction in HbA1c (%) from baseline to the end of 12 weeks. Timepoint: From baseline to the end of 12 weeks	—

Measure

Time frame

•The percentage of patients with improvement in Time in Range (TIR) from the baseline (first 2 weeks) to the end of 12 weeks (last 2 weeks) •The percentage of patients with reduction in Time above Range (TAR) from the baseline (first 2 weeks) to the end of 12 weeks (last 2 weeks) •The percentage of patients with improvement in Time below Range (TBR) from the baseline (first 2 weeks) to the end of 12 weeks (last 2 weeks) •The percentage of patients with improvement in FBG (mg/dL) from baseline to the end of 12 weeks. •The percentage of patients with improvement in PPBG (mg/dL) from baseline to the end of 12 weeks. •The percentage of patients with reduction in HbA1c (%) from baseline to the end of 12 weeks. Timepoint: From baseline to the end of 12 weeks

—

Secondary

Measure	Time frame
• Change in the BMI (kg/m2) from baseline to the end of 12 weeks. • Change in the waist circumference (cm) from baseline to the end of 12 weeks. • Change in Serum LDL, Serum HDL, Serum VLDL, Serum Triglyceride and Total Cholesterol (mg/dL) from baseline to the end of 12 weeks. • Change in BCA Parameters like Skeletal Muscle Mass(kg) and Body Fat Mass (kg) from baseline to the end of 12 weeks. Timepoint: From baseline to the end of 12 weeks	—

Measure

Time frame

• Change in the BMI (kg/m2) from baseline to the end of 12 weeks. • Change in the waist circumference (cm) from baseline to the end of 12 weeks. • Change in Serum LDL, Serum HDL, Serum VLDL, Serum Triglyceride and Total Cholesterol (mg/dL) from baseline to the end of 12 weeks. • Change in BCA Parameters like Skeletal Muscle Mass(kg) and Body Fat Mass (kg) from baseline to the end of 12 weeks. Timepoint: From baseline to the end of 12 weeks

—

Countries

India

Contacts

Public ContactDr Krunal Chaudhari

Diabetes Care and Hormone Clinic

banshisaboo@hotmail.com8208716680

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026